The Claim

Apigenin reduces the adhesion of THP-1 monocytic cells to human endothelial cells stimulated with DEHP.

Source: Apigenin Inhibits the Expression of IL-6, IL-8, and ICAM-1 in DEHP-Stimulated Human Umbilical Vein Endothelial Cells and In Vivo

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
12score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

Apigenin decreases the sticking of immune cells to blood vessel lining cells when those cells are exposed to DEHP, a chemical linked to vascular inflammation.

See the scientific wording

Apigenin reduces the adhesion of THP-1 monocytic cells to DEHP-stimulated human endothelial cells, indicating a potential role in limiting leukocyte recruitment during vascular inflammation.

Why this might work

Apigenin blocks a specific signaling pathway in blood vessel cells that is turned on by a toxic chemical, which stops the cells from producing a sticky protein. Without this protein, immune cells cannot attach to the blood vessel wall.

Supported mechanismbased on 1 study

What the research says

1 study

  1. Study: Apigenin Inhibits the Expression of IL-6, IL-8, and ICAM-1 in DEHP-Stimulated Human Umbilical Vein Endothelial Cells and In Vivo

    Apigenin, a natural compound, was shown to stop immune cells from sticking to damaged blood vessel walls in a lab experiment, which could help reduce inflammation. It works by blocking a signal that makes the walls 'sticky'.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.